Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
作者信息
de Vries M K, Wolbink G J, Stapel S O, de Groot E R, Dijkmans B A C, Aarden L A, van der Horst-Bruinsma I E
出版信息
Ann Rheum Dis. 2007 Jan;66(1):133-4. doi: 10.1136/ard.2006.057745.
Abstract
摘要
相似文献
1
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
Ann Rheum Dis. 2007 Jan;66(1):133-4. doi: 10.1136/ard.2006.057745.
2
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
Ann Rheum Dis. 2007 Sep;66(9):1252-4. doi: 10.1136/ard.2007.072397. Epub 2007 May 1.
3
Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
Ann Rheum Dis. 2009 Nov;68(11):1787-8. doi: 10.1136/ard.2009.109702.
4
[New results from studies of therapy of ankylosing spondylitis with infliximab].
Z Rheumatol. 2003 Apr;62(2):108-9. doi: 10.1007/s00393-003-0501-3.
5
Treatment of ankylosing spondylitis with infliximab.
Ann Rheum Dis. 2001 Dec;60(12):1159-60. doi: 10.1136/ard.60.12.1159.
6
Persistence of Infliximab in Circulation for 7 Years?
Clin Chem. 2015 Nov;61(11):1420-1. doi: 10.1373/clinchem.2015.242024.
7
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.
Ann Rheum Dis. 2013 Oct;72(10):1605-12. doi: 10.1136/annrheumdis-2012-203091. Epub 2013 May 16.
8
Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Ann Rheum Dis. 2008 Sep;67(9):1354. doi: 10.1136/ard.2007.082537.
9
Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
Ann Rheum Dis. 2013 Jul;72(7):1265-7. doi: 10.1136/annrheumdis-2012-203169. Epub 2013 Mar 12.
10
The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
Clin Exp Rheumatol. 2010 Sep-Oct;28(5):661-8. Epub 2010 Oct 22.
引用本文的文献
1
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies.
Front Immunol. 2020 Aug 18;11:1951. doi: 10.3389/fimmu.2020.01951. eCollection 2020.
2
An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision.
Ther Adv Musculoskelet Dis. 2020 Jun 24;12:1759720X20934277. doi: 10.1177/1759720X20934277. eCollection 2020.
3
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
Clin Transl Sci. 2020 Jul;13(4):743-751. doi: 10.1111/cts.12760. Epub 2020 Apr 1.
4
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.
Antibodies (Basel). 2019 Dec 4;8(4):56. doi: 10.3390/antib8040056.
5
Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis.
Rheumatol Int. 2019 May;39(5):841-849. doi: 10.1007/s00296-019-04288-7. Epub 2019 Mar 21.
6
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.
Nat Rev Rheumatol. 2017 Nov 21;13(12):707-718. doi: 10.1038/nrrheum.2017.187.
7
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.
Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017.
8
Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.
J Immunol Res. 2016;2016:2342187. doi: 10.1155/2016/2342187. Epub 2016 Aug 8.
9
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.
Clin Pharmacokinet. 2016 Jul;55(7):789-805. doi: 10.1007/s40262-015-0361-4.
10
The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
PLoS One. 2015 Nov 13;10(11):e0142930. doi: 10.1371/journal.pone.0142930. eCollection 2015.
本文引用的文献
1
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.
Arthritis Rheum. 2006 Mar;54(3):711-5. doi: 10.1002/art.21671.
2
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Rheumatology (Oxford). 2005 May;44(5):670-6. doi: 10.1093/rheumatology/keh584. Epub 2005 Mar 9.
3
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
Arthritis Rheum. 2005 Feb;52(2):582-91. doi: 10.1002/art.20852.
4
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
Ann Rheum Dis. 2003 Sep;62(9):817-24. doi: 10.1136/ard.62.9.817.
5
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.
Arthritis Rheum. 1984 Apr;27(4):361-8. doi: 10.1002/art.1780270401.
Zotero 插件